AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Study to Investigate Effects of Omega-3 Carboxylic Acids and Dapagliflozin on Liver Fat Content in Diabetic Patients
Phase 2
Completed
- Conditions
- T2 Diabetes and Fatty Liver Disease (Non-alcoholic Origin)
- Interventions
- First Posted Date
- 2014-10-31
- Last Posted Date
- 2017-03-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 223
- Registration Number
- NCT02279407
- Locations
- 🇸🇪
Research Site, Örebro, Sweden
An Observational Study of Respiratory Syncytial Virus (RSV) Hospitalizations in Preterm Infants
Completed
- Conditions
- Respiratory Syncytial Virus Hospitalizations
- First Posted Date
- 2014-10-24
- Last Posted Date
- 2017-05-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 497
- Registration Number
- NCT02273882
- Locations
- 🇺🇸
Research Site, Marshfield, Wisconsin, United States
🇺🇸Winthrop University Hospital, Mineola, New York, United States
Evaluate the Efficacy and Safety of Saxagliptin in Combination With Metformin IR Compared to Saxagliptin Monotherapy and to Metformin IR Monotherapy in Drug Naive Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control
Phase 3
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: Placebo 5 mg for SaxagliptinDrug: Placebo 500 mg for metformin (with titration)
- First Posted Date
- 2014-10-23
- Last Posted Date
- 2018-02-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1136
- Registration Number
- NCT02273050
- Locations
- 🇨🇳
Research Site, Yueyang, China
Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase 2
Completed
- Conditions
- Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation
- Interventions
- First Posted Date
- 2014-10-23
- Last Posted Date
- 2023-10-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 95
- Registration Number
- NCT02272790
- Locations
- 🇳🇱
Research Site, Amsterdam, Netherlands
Utilization of Ticagrelor in the Upstream Setting for Non-ST-Segment Elevation Myocardial Infarction (UPSTREAM): An ED-Based Clinical Registry
Completed
- Conditions
- Acute Coronary Syndromes
- Interventions
- Other: Non-Interventional Study
- First Posted Date
- 2014-10-22
- Last Posted Date
- 2020-11-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2000
- Registration Number
- NCT02271022
- Locations
- 🇺🇸
Research Site, Milwaukee, Wisconsin, United States
A Phase3 Study to Evaluate the Efficacy and Safety of MEDI3250 in Healthy Japanese Children Age 7 Years Through 18 Years
Phase 3
Completed
- Conditions
- Healthy Japanese Children Age 7 Years Through 18 Years
- Interventions
- Drug: Placebo
- First Posted Date
- 2014-10-21
- Last Posted Date
- 2017-04-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1369
- Registration Number
- NCT02269475
- Locations
- 🇯🇵
Research Site, Yokkaichi-shi, Japan
A Phase 3 Open-label Study to Evaluate the Safety of MEDI3250 in Healthy Japanese Children Age 2 Years Through 6 Years
Phase 3
Completed
- Conditions
- Healthy Japanese Children Age 2 Years Through 6 Years
- Interventions
- First Posted Date
- 2014-10-21
- Last Posted Date
- 2015-09-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 100
- Registration Number
- NCT02269488
- Locations
- 🇯🇵
Research Site, Tsu-shi, Japan
Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes
Phase 3
Completed
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- First Posted Date
- 2014-10-20
- Last Posted Date
- 2018-09-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 833
- Registration Number
- NCT02268214
- Locations
- 🇬🇧
Research Site, Welwyn Garden City, United Kingdom
Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents
Phase 1
Active, not recruiting
- Conditions
- Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer
- Interventions
- First Posted Date
- 2014-10-15
- Last Posted Date
- 2025-06-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 357
- Registration Number
- NCT02264678
- Locations
- 🇬🇧
Research Site, Withington, United Kingdom
OSCA - Olaparib Standard of CAre Study
Completed
- Conditions
- Platinum-sensitive Recurrent Serous Ovarian Cancer
- Interventions
- Other: Data Collection
- First Posted Date
- 2014-10-13
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2123
- Registration Number
- NCT02262273
- Locations
- 🇬🇧
Research Site, Wolverhampton, United Kingdom